In a surprise move, Bristol-Myers Squibb announced that it will acquire Celgene for $74 billion in stock and cash – roughly a 54% premium. Finally, a new R&D organization will arise for the new company. Caforio believes that this major acquisition is important for the future of Bristol-Myers Squibb. But he needs to get real about what he is putting his R&D organization through. That’s the scenario at Bristol-Myers Squibb for the foreseeable future.

Source: Forbes January 03, 2019 20:56 UTC